Back to all studies
UnknownNCT06359899

Safety study of AK0901 in ADHD

This study has public registry information in China. It is testing AK0901 for ADHD.

ADHDDrugFrom 6 Years to 12 Years
Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT06359899. We help you review the study, but cannot decide medical eligibility.
In plain English

Key information made simple

What is this study testing?

This study is testing whether a study medication may be useful for children experiencing ADHD.

What would participation involve?

Participants may receive a study medication, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in China.

Who is it mainly for?

This study appears to be mainly for children with ADHD. Because it involves minors, a parent or guardian may need to be involved.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.

What to expect

Your next step

The official record suggests in-person participation through a hospital, with sites including Beijing anding hospital capital medical university and Peking university sixth hospital in Beijing. Participation appears to involve using a digital tool or support program and giving feedback through check-ins or assessments. The main fit is usually matching the main diagnosis and being able to follow the planned visits or tasks, while common reasons not to take part include major medical issues that could make participation unsuitable and safety concerns that need urgent care first. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateEstimated: May 2024
Recruitment status
Unknown
Estimated enrollment
Not clearly listed
Sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Not clearly listed
Locations
China
Age range
From 6 Years to 12 Years
Official registry ID
NCT06359899
Official title
A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT06359899. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in China.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring digital app or tool for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.

Who might this study be for?

This study may concern people with adhd; age range: From 6 Years to 12 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Shanghai Ark Biopharmaceutical Co., Ltd., which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The recruitment status is not clearly listed. Check the official registry or contact the study team.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me